An Overview on Guillain Barre Syndrome

Authors

  • Alekhya Reddy Gantala
  • Tejaswini Gangadhara Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India
  • Niharika Rakam Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India
  • Rohith Kumar Kadarla Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

DOI:

https://doi.org/10.22270/ajprd.v7i5.567

Keywords:

cerebro spinal fluid, peripheral neuropathy, Guillain Barre Syndrome

Abstract

Guillain Barre Syndrome is a peripheral neuropathy that causes acute neuromuscular failure. Guillain, Barré and Strohl used Quinckes method to determine the protein level and cell count in the cerebro spinal fluid of their patients. In 1956, Charles Miller Fisher reported three patient case histories in the New England Journal of Medicine. Guillain-Barré syndrome is rare, incidence worldwide is estimated to be 0.6-4/100,000 person/year and men are about 1.5 times more affected than women. Awareness of these complications, their detection and management may help limit the morbidity of GBS.

 

 

Downloads

Download data is not yet available.

Author Biographies

Tejaswini Gangadhara, Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Niharika Rakam, Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Rohith Kumar Kadarla, Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

Department of Pharmacy Practice, Sree Chaitanya Institute of Pharmaceutical Sciences, Thimmapur, Karimnagar, Telangana, India

References

1. Vuci CS, Kiernan MC, Cornbl Athdr Guillain-Barre syndrome: anupdat e.JCl in Neurosci.2009; 16:733-741.
2. Kuwabar A, S.Guillain Barré syndrome: epidemiology, pathophysiology and management. Drugs, 2004; 64(6):597610.
3. Vanden Berg B. Walgaard C, Drenthen J , Fokke C, Jacob BC, van Doorn PA, Guillain Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.Nat .Rev .Neurol.2014; 10(8):469482.
4. Lehmann HC, Hughes RA, Kieseier BC, Hartung, HP, Recent developments and f uture direction i n Guillain Barré syndrome.J.Per i pher .Ner v .Syst . 2012; 17(3): 5770.
5. Jacobs BC, Rothbarth PH.vander Meché FG, Herbrink P,Schmitz PI,DeKler, MA, Vandoorn PA.The spectrum of antecedent infect ionsin Guill ainBarré syndrome: acasecont rol study .Neurology,1998; 51(4):1110-1115.
6. Yuki, N. Hartung, H. P.Guillain Barré syndrome. N.Engl .J. Med. 2012; 366(24):22942304.
7. Gullain G., Barré,J.A.&Strohl, A.Radiculo neuritis syndrome with hhy peral buminosi sofcerebros pinal fluid without cellularre action. Noteson clinical features and graph soft end on reflexes. Ann. Med. Interne ( Par i s)1999; 150:24-32.
8. Pearce J M. Walter Essex Wynter, Quincke, and lumbarpunctur e.J. Neurol .Neurosurg. Psychiatr1994; 57:179.
9. Fokke C.et al .Di agnosi s of Guil lai n-Bar ré syndr ome and v al idat ion of Bright on criteria. Brain, 2014; 37: 33-43.
10. Fisher MA nunusual variant of acut eidiopathic polyneurit is( syndr ome of ophthalmo plegia, ataxi aandar eflexia) .N.Engl .J. Med.1956; 255:57-65.
11. Vucic S, Kiernan MC, Cornblath DR, Guillain-Barre syndrome: anupdat e.JCl in Neurosci.2009; 16:733-741
12. Van Doorn PA, Ruts L, Jacobs BC.Clinical features, pathogenesis, and treatment of Gui llain Bar r é syndrome. Lancet Neur ol. 2008; 7(9):3950.
13. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, etal . Electro physiological classification of Guillain Barr é syndrome: cl inical associations and out come. Plasma Exchange/S and oglobul i n Guillain Barré Syndr ome Trial Group.AnnNeurol 1998; 44: 7808.
14. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological , clinical , and elctro diagnostic findings in childhood Guillain Barré syndrome: areappr ai sal .AnnNeurol, 1999; 46: 7017.
15. Rees JH, Thompson RD, Smeeton NC, etal .Epidemiological study of Gui l lain Bar r é syndrome in southeast Engl and.J Neurol Neurosurg Psychi at r y, 1998; 64: 74-7.
16. Govoni V, Granieri E, Casetta I , etal .The incidence of Guillain Barrésyndr ome in Ferrara, Italy : is the disease really increasi ng?JNeurol Sci 1996; 137: 62—8.
17. Jiang GX, dePedro Cuesta J, Fredrikson S.Guill ain Barr ém syndrome mein sout h west Stockholm, 1973-1991.1.Quality of registered hospital d i a g n o s e s and incidence.Act aNeur ol Scand1995; 91: 109-17.
18. McLeanM, Ducl osP, JacobP, etal .Incidence of Guill ainBarr é syndr omein Ontario and Quebec, 1983-1989, using hospital service dat abases.Epidemiology1994; 5: 443-8.
19. SedanoMJ, Calleja J, Canga E, etal .Guillain Barré syndrome in Cantabri a, Spain.An epidemiological and clinical study .Acta Neurol Scand1994; 89: 287-92.
20. Jiang GX, ChengQ, Link H, etal .Epidemiological features of Guillain Barr é syndrom ein Sweden, 1978-93.JNeurol Neurosurg Psychiatry1997; 62: 447-53.
21. Hankey GJ.Guillain Barré syndrome in Western Australia, 1980-85. MedJAust 1987; 146: 130-3.
22. Beghi E, Kurl and LT, Mulder DW, etal .Gui llai n Bar r é sy ndr ome: clinico epidemiologic features and eVectofinfluenzav accine.Arch Neurol 1985; 42: 1053-7.
23. Pedro Cuest aJ, Abraira V, Jiang GX, etal . Guilain Barré syndrome in sout hwest Stockholm, 1973-1991.3.Clinico epidemiological sub groups.Act aNeurol Scand1996; 93: 175-83.
24. Landry O. Note surlaparaly sieascendant eaigue. Gazette Hebdomadai r ede Medici n 1859; 6: 472-4; 486-8.
25. Winer JB, Hughes RAC, Anderson MJ, etal .Aprospective study of acute idiopat hicneuropat hy .I I .Ant ecedent event s.JNeurol Neurosurg Psychi at ry 1988; 51: 613-18.
26. The Italian Guillain Barré Study Group. The prognosis and mainpr ognostic indicators of Guillain Bar r é syndrome: amulticentre prospective study of 297 patients.Brain1996; 119: 2053-61.
27. ReesJH, Soudain SE, Gregson NA, etal .Campylobacterjejuni infections and Guillain Barré syndrome.NEngl JMed1995; 333: 1374-9.
28. Winer JB, Hughes RAC, Osmond C. Aprospective study of acute idiopathic neur opat hy I . Clinical features and theirprognostic value.JNeur ol Neurosurg Psychiatry 1998; 51: 605-12.
29. DeJager AE, Sluiter HJ.Clinical signsin severe Guillain Barré syndrome: analysis of 63 patients.JNeur ol Sci 1991; 104: 143-50.
30. Winer JB, Hughes RA, Ander son MJ, Jones DM, Kangro H, Watki ns RP. Aprospective study of acut eidiopathic neuropathy .I I .Antecedent event s.J Neurol Neurosurg Psychiatry 1988; 51: 6138.
31. Haber P, De Stefano F, Angulo FJ, Iskander J, Shadomy SV, Weintr aub E, etal .Guillain Barré syndrome following influenza vaccination. JAMA2004; 292: 247881.
32. AwongI E, Dandur and KR, Keeys CA, Maung Gyi FA.Drug associated Guillain Barré syndrome: Aliter at ure rev i ew.Ann Pharmacother1996; 30: 17380.
33. Fagius J, Osterman PO, Sidén A, Wiholm BE.Guillain Barré syndrome fol lowing zimeldine treatment .J Neurol Neurosurg Psychiatry1985; 48: 659.
34. Raschetti R, Maggini M, Popoli P, Caffari B, Da Cas R, Mennii I ppolito F, etal .Gangliosides and Guillain Barré syndrome. JCl in Epidemiol 1995; 48: 1399405.
35. Okuyan E, Cakar MA, Dinckal MH.Guillain Barré syndrome after thr ombolysis wi th streptokinase.Cardiol Res Pract 2010; 2010: 315856.
36. ht t ps: / / www. medical news today . Com/ ar t i cl es/ 167892. php.
37. Yuki N, Taki T, I nagaki F, etal . Abacteriuml ipopoly saccharid ethatelicits Guillain Barré syndrome hasa GM 1 ganglio side like structur e.JExpMed1993; 178: 1771-5
38. Jacobs BC, van Doorn PA, Groenev eld JH, etal .Cytomegalo virus infecti ons and anti GM2 antibodies i n Guillain Bar r é syndrome.J Neurol Neur osurg Psychiatry1997; 62: 641-3.
39. Yuki N, TagawaY.Acute cytomegalo virus infection and IgM anti GM2 antibody .JNeur ol Sci 1998; 154: 14—17.
40. Goddar dEA, Lastovica AJ, Argent AC. Campylobact er 0: 4isolation in Guillain Bar r é syndrome. Arch Di s Chi l d1997; 76: 5268.
41. Yuki N.Molecular mimicry bet ween ganglio sides and lipopol y sacchar i des of Campylobacter jej uni i sol ated from pati ent swi th Gui l l ai n Bar r ésyndr ome and Mi l l er Fisher sy ndrome.JI nfect Di s 1997; 176( suppl 2) : S1503.
42. Chi baA, Kusunoki S, Obat aH, Machinami R, KanazawaI. Serumant i GQ1bIg Ganti body is associated with ophthalmo plegiain Miller Fi sher syndrome and Gui l l ai nBar r ésy ndr ome: cl i ni cal andi mmunohi st ochemi cal st udi es.Neur ol ogy1993; 43: 19117.
43. Roberts M, Willison H, VincentA, Newsom Davis J.Serumf actori n Mi l ler Fi sher vari ant of Gui l l ai n Bar r é syndromeandneur ot r ansmi t t err el ease . Lancet 1994; 343: 4545
44. Yuki N, I chi hashi Y, Taki T. Sub class of Ig Ganti body to GM1 epitopebearing li popoly saccharide of Campylobacter jejuni i n patient swi t h Guillain Barrésyndrome.JNeuroimmunol 1995; 60: 1614
45. Griffin JW, Li CY, MackoC, HoTW, Hsi ehST, XueP, etal .Earl ynodalchangei t h acute motoraxonal neuropat hy patter n of t he Gui l l ai nBar r ésyndrome.J Neurocy tol1996; 25: 3351
46. Winer J, Hughes S, Cooper J, Ben Smith A, Savage C. Gamma delta Tcel l sinfiltrating sensoryner vebiopsies from patient swit h inflammatoryneur opathy .JNeurol 2002; 249: 61621.
47. Kai da K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, et al . Ganglioside complex esasnewtarget antigens in Gui l l ai nBar r ésy ndr ome.AnnNeur ol 2004; 56: 56771.
48. Asbur yAK, Cor nbl at hDR.Assessmentofcur r entdi agnost i ccr i t er i af orGui l l ai nBar r é sy ndr ome.AnnNeur ol 1990; 27( suppl ) : S21—4.
49. Wi nerJB, HughesRAC, OsmondC.Aprospectivestudy of acute idiopathi cneur opat hy .I . Clinical features and the irprognostic val ue.JNeur ol Neur osur gPsy chiat ry1998; 51: 605—12.
50. Thornton CA, Latif AS, Emmanuel JC.Guill Barré syndrome associat ed with human immune deficiency virus infection in Zimbabwe.Neurol ogy1991; 41: 812—15.
51. Saf r anekTJ, Lawr enceDN, Kur l andLT, etal .Reassessmentoft heassoci at i onbet ween Gui l l ai nBar r ésy ndr omeandr ecei ptofswi nei nfluenzav acci nei n1976—1977: r esul t sofa t wost at est udy .Exper tNeur ol ogyGr oup.AmJEpi demi ol 1991; 133: 940—51.
52. Mc Khann GM, Cornblath DR, GriYn JW, etal .Acute motoraxonal neur opathy : afrequentcause of acute flaccidparaly sisin China.Ann Neurol 1993; 33:333—42.
53. Asbury AK, Cornblath DR. Assessment of current diagnstic criteria for Guillain Bar ré sy ndrome.AnnNeur ol 1990; 27: S21-4.
54. Byun WM, Park WK, Park BH, etal .Guillain Barré syndrome: MR imagi ng finding soft hespineineight patients.Radiology1998; 208:137-41.
55. Gorson KC, Ropper AH, Muriello MA, etal .Prospective evaluation of MRI lumbosacral nerve root enhancement i n acute Guillai n Bar r é syndr ome. Neurology1996; 47: 813-17.
56. The Guiliai n Ba ré Syndrome Study Group. Plasma pheresisand acute Guillain Barr é syndrome. Neurology1985; 35:1096-104.
57. French Cooper ative Group on Pl asma Exchangein Guillain Barré Sy ndrome.Plasma exchangein Guillain Barré syndrome: one year foll owup. Ann Neurol 1992; 32: 94-7.
58. The Fr ench Cooper at iv e Gr oup on Pl asma Exchange i n Guillain Barré Syndrome.Appropriate number of pl asma exchangesi n Guillain Barré Syndrome.AnnNeur ol 1997; 41: 298-306.
59. Plasma Exchange/Sandoglobul in Guillain Barré SyndromeTrial Group. Randomised trial of plasma exchange, intravenous immuno globulin, and combined treatment s in Guilla i n Barr é sy ndrome. Lancet1997; 349: 225
60. Kleyweg RP, vander Meche FGA, Meultee J. Treat ment of Guillain Barr ésyndome with high dose gamma globulin. Neurology1988; 38: 1639-41.
61. Plasma Exchange/ Sandoglobul in Guillain Barré Syndrome Trial Gr oup.Randomised trial of plasma exchange, intravenous immunoglobulin, and combi ned treat ment s in Guillain Bar r é syndrome.Lancet1997; 349: 225
62. Korint henberg R, Monting JS.Natural history and treatmenteVectsin Guill ai n Bar r ésy ndr ome: amulticentre study .Ar ch Di s Child1996; 74: 281.
63. The Dutch Gui l l ai n Bar r é St udy Group.Treat ment of Gui l l ai n Bar r ésy ndrome with high dose immunoglobulins combined wit h methyl predni solone: apilot study .Ann Neurol 1994; 35: 749-52.
64. Rees JH, Thompson RD, Smeeton NC, Hughes RA.Epidemiological st udy of Guillai n Barré syndrome i n south east England. JNeur ol Neur osurg Psychiat ry. 1998; 64: 747.
65. Winer JB, Hughes RA, Osmond C.Apr ospective study of acut eidiopathi c neuropathy . I . Cli nical featur es and thei rpr ognostic value. JNeurol Neur osur gPsychiatry 1988; 51: 60512.
66. HughesRA, Wi j di cksEF, BensonE, Cor nbl at hDR, HahnAF, Mey t hal erJM, etal , Mul t i di sci pl i nar yConsensusGr oup.Suppor t i v ecar ef orpat i ent swi t hGui l l ai nBar r ésy ndr ome. Ar chNeur ol 2005; 62: 11948.
67. LawnN, Fl et cherD, Hender sonR, Wol t erT, Wi j di cksE.Ant i ci pat i ngmechani cal v ent i l at i oni n Gui l l ai nBar r ésy ndr ome.Ar chNeur ol 2001; 58: 8938.
68. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guil lai n Barré syndr ome. Cochrane Database Syst Rev2002; (2):CD001798.
69. Plasma Exchange/Sandoglobulin Guillain-Barre´ Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre ´ syndrome. Lancet.1997; 349(9047):225-230.
70. Bosch EP, Smith BE. Disorders of peripheral nerves. In: Bradly WG, Daroff RB, Fenichel GM, Jankovic J, eds. Neurology in Clinical Practice. 4th ed. Philadelphia: Elsevier; 2004; 2336-2345.
71. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. Epidemiological study of Guillain-Barre´ syndrome in south east England. J Neurol Neurosurg Pscyh. 1998; 64(1):74-77.
72. Guillain-Barre´ Study Group. Guillain-Barre´ syndrome: an Italian multicentre case-control study. Neurol Sci. 2000; 21(4):229-234.
73. French Cooperative Group on Plasma Exchange in Guillain-Barre ´ syndrome. Efficiency of plasma exchange in Guillain-Barre´ syndrome: role of replacement fluids. Ann Neurol. 1987; 22(6): 753-761.
74. French Cooperative Group on Plasma Exchange in Guillain-Barre ´ Syndrome. Appropriate number of plasma exchanges in Guillain-Barre´ Syndrome.Ann Neurol. 1997; 41(3):298-306.
75. Nguyen TN, Badjatia N, Malhotra A, Gibbons FK, Qureshi MM, Greenberg SA. Factors predicting extubation success in patients with Guillain-Barre´ syndrome. Neurocritical Care. 2006; 5(3): 230-234.
76. Ali MI, Ferna´ndez-Pe´rez ER, Pendem S, Brown DR, Wijdicks EFM, Gajic O. Mechanical ventilation in patients with Guillain-Barre´ syndrome. Respir Care. 2006; 51(12): 1403-1407.
77. Ropper AH, Kehne SM. Guillain-Barre´ syndrome: Management of respiratory failure. Neurology. 1985; 35(11):1662-1665.
78. Hughes RAC, Wijdicks EFM, Benson E, et al. Supportive care for patients with Guillain-Barre´ syndrome. Arch Neurol. 2005; 62(8):1194-1198.
79. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barre ´ Syndrome. Contemporary Neurology Series. Philadelphia: FA Davis; 1991.
80. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barre ´ Syndrome. Contemporary Neurology Series. Philadelphia: FA Davis; 1991.
81. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EFM. Adynamic ileus in severe Guillain-Barre´ syndrome. Muscle Nerve. 2001; 24(7):963-965.
82. Sakakibara R, Uchiyama T, Kuwabara S, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barre´ syndrome. Neurourol Urodynam. 2009; 28(5):432-437.
83. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barre´ syndrome. J Neurol Neurosurg Psychiatry. 1997; 63(5):649-653.
84. Sakakibara R, Uchiyama T, Kuwabara S, etal. Prevalence and mechanism of bladder dysfunction in Guillain-Barre´ syndrome. Neurourol Urodynam. 2009; 28(5):432-437.
85. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barre´ syndrome. J Neurol Neurosurg Psychiatry. 1997; 63(5):649-653.
86. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition). Chest. 2008; 133(6):381S-453S.
87. Hughes RAC, Wijdicks EFM, Benson E, et al. Supportive care for patients with Guillain-Barre´ syndrome. Arch Neurol. 2005; 62(8):1194-1198.
88. Roubenoff RA, Borel CO, Hanley DF. Hypermetabolism and hypercatabolism in Guillain-Barre´ syndrome. J Parenter Enteral Nutr. 1992; 16(5):464-472.
89. Hughes R.A., Cornblath D.R., Guillain-barre syndrome. The Lancet, 2005; 366(9497): 1653-66.
90. Hughes R.A., Swan A.V., van Doorn P.A., Intravenous immunoglobulin for Guillain‐Barré syndrome. The Cochrane Library, 2010.
91. McGrogan A., Madle G., Seaman H., DeVries C.S. Epidemiology of Guillain-Barré Syndrome worldwide. A systemic literature review. Neuroepidemiology, 2009; 32:150-63.
92. Ang CW, Jacobs BC, Laman JD. The Guillain Barre Syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25:61-6.
93. Hughes R. Guillain-Barrésyndrome. London: Springer-Verlag, 1990.
94. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014; 137: 33-43.
95. Hadden RD, Cornblath DR, Hughes RA, et al, for the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44: 780—88.
96. Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conductionblock in acute motor axonal neuropathy. Brain 2010; 133: 2897-908.
97. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 2Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 4General Paediatrics OperativeUnit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Sicily Italy.

Published

2019-10-15

How to Cite

Gantala, A. R., Gangadhara, T., Rakam, N., & Kadarla, R. K. (2019). An Overview on Guillain Barre Syndrome. Asian Journal of Pharmaceutical Research and Development, 7(5), 103–112. https://doi.org/10.22270/ajprd.v7i5.567

Issue

Vol. 7 No. 5 (2019): Vol 7 No 5 (2019): Volume 7 Issue 5 Sept - Oct. 2019

Section

Review Articles

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).